文献速递血管炎

奥妥珠单抗治疗ANCA相关性血管炎

Obinutuzumab as treatment for ANCA-associated vasculitis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本文报告3例对利妥昔单抗发生过敏反应的ANCA相关性血管炎患者,改用奥妥珠单抗治疗后耐受良好,并在诱导疾病缓解、实现B细胞完全耗竭及血清ANCA滴度降至检测不到方面有效;3例均再次接受奥妥珠单抗维持缓解。作者认为奥妥珠单抗似乎安全有效,但需开展前瞻性研究比较其与利妥昔单抗。

要点

  • 3例对利妥昔单抗过敏的ANCA相关性血管炎患者接受奥妥珠单抗,耐受良好。
  • 奥妥珠单抗在诱导缓解、B细胞完全耗竭及ANCA滴度降至检测不到方面有效。
  • 3例均再次接受奥妥珠单抗维持缓解,作者认为需前瞻性研究比较两药。

核心结论

  • 奥妥珠单抗似乎是对利妥昔单抗难治或曾发生过敏反应的ANCA相关性血管炎患者安全有效的治疗。
  • 作者认为需开展前瞻性研究,在ANCA相关性血管炎患者中比较利妥昔单抗与奥妥珠单抗。

研究设计与样本

  • 病例系列研究,纳入3例因对利妥昔单抗有过敏反应史而接受奥妥珠单抗治疗的ANCA相关性血管炎患者。

主要发现

  • 1例女性显微镜下多血管炎和2例男性肉芽肿性多血管炎患者接受了奥妥珠单抗。
  • 尽管既往对利妥昔单抗发生过敏反应,全部患者对奥妥珠单抗治疗耐受良好。
  • 奥妥珠单抗治疗在诱导疾病缓解、诱导B细胞完全耗竭及使血清ANCA滴度降至检测不到方面有效。
  • 全部3例患者均再次接受奥妥珠单抗以维持缓解。

局限性

  • 原文报告为3例的病例系列研究。
  • 作者在结论中提出需开展前瞻性研究,在ANCA相关性血管炎患者中比较利妥昔单抗与奥妥珠单抗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rituximab is a standard of care therapy for patients with ANCA-associated vasculitis. When rituximab is contraindicated, or in the case of refractory disease, other treatments are needed. Obinutuzumab is another anti-CD20 antibody for the treatment of haematological malignancies that may induce a deeper B cell depletion compared with rituximab. This article reviews three cases of patients with ANCA-associated vasculitis who were treated with obinutuzumab due to their history of anaphylactic reactions to rituximab. METHODS: Case series of three patients with ANCA-associated vasculitis treated with obinutuzumab. RESULTS: One female patient with microscopic polyangiitis and two male patients with granulomatosis with polyangiitis received obinutuzumab. The treatment was well-tolerated in all patients despite previous anaphylactic reaction to rituximab. Treatment with obinutuzumab was effective in (i) inducing disease remission, (ii) inducing total B cell depletion, and (iii) resulting in undetectable serum titres of ANCA. All three patients were re-treated with obinutuzumab for maintenance of remission. CONCLUSION: Obinutuzumab appears to be a safe and efficacious therapy for patients with ANCA-associated vasculitis who have had refractory disease or a history of anaphylaxis to rituximab. Prospective studies comparing rituximab to obinutuzumab in ANCA-associated vasculitis patients are warranted.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Amudala NA, Boukhlal S, Sheridan B, et al. Obinutuzumab as treatment for ANCA-associated vasculitis. Rheumatology (Oxford). 2022. PMID: 34958343. doi:10.1093/rheumatology/keab916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。